세포 기반 어세이 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Cell-based Assays Market Growth & Trends:

The global cell-based assays market size is expected to reach USD 33.8 billion by 2030, registering a CAGR of 8.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. A rise in demand for cell-based assays will drive the market. Cell-based assays effectively aid in acceleration and thereby, enhancement of drug development. This helps therapeutic drugs to be supplied robustly to cater to the industry demand. For instance, these are used in lead candidate selection and provide invaluable information about therapeutic action mechanisms, drug efficacy, safety, and toxicity tests. Wide applications of these assays in drug development processes are expected to boost the demand. These assays are integral to the drug development process by adopting several technologies, such as CRISPR-Cas9, to allow easy resolution of mutations, knock-ins & knockouts of a specific marker at a precise location on the genome or a given culture of cells.

For instance, Celprogen's human pancreatic cancer cell line characterization kit is a cell-based ELISA kit that is used for the measurement of the concentration of a protein in cells for the determination of the differentiation status of stem cells, thereby eliminating the need to prepare cell lysates and is widely applicable for drug discovery. On the other hand, key players are undertaking various growth strategies to expand their pipelines, portfolios, and offerings to penetrate the market better. For instance, in July 2022, Mission Bio, Inc., launched assay for the detection of solid tumors through its pharma assay development services to aid the acceleration of the development process of cancer therapeutics by reducing the time & cost to characterize solid tumors.

Moreover, in April 2022, Porvair Sciences exhibited Chromatrap chip kits for epigenetics along with a new range of assay and newly designed cell culture microplates for high throughput screening process, cell growth, and proliferation at the American Association for Cancer Research. Many researchers and clinicians believe that there is a strong necessity for novel cell-based assays for their utility in diagnostics and to devise new therapeutic regimes to effectively combat the growing burden of autoimmune diseases, infectious diseases, and genetic disorders across the globe. Furthermore, the COVID?19 pandemic was substantially disruptive both to the continuance of research activities and the type of assays performed.

There are efforts across the U.S. to ensure re-igniting the research activities inclusive of all kinds of cell-based assays. These assays are used for the detection of COVID-19 infection as well. For instance, in May 2020, AcroBiosystem launched a flow cytometry assay to study the binding between ACE2 and S1 protein/S1 RBD protein, thus can be utilized for neutralizing antibody screening. North America dominated the global industry in 2021 owing to an increasing number of biotechnology research studies, growing research on therapeutic drugs, the presence of key players, and the high prevalence of cancer. Asia Pacific is expected to register the fastest CAGR from 2022 to 2030 due to the rising demand for research in life sciences and increased genetic level understanding of diseases.

Cell-based Assays Market Report Highlights:

• The assay kits products segment accounted for the largest revenue share in 2023 due to the utilitarian benefits that a test kit could offer to clinicians, researchers, and the normal population.
• Ready-to-use kits and self-administrable diagnostic kits are increasingly trending these days.
• The drug discovery application segment is expected to grow at a lucrative CAGR over the forecast period.
• This is due to a rise in the number of researches for therapeutic drug discovery, an increasing number of FDA approvals, and a rise in demand for novel therapeutic drugs coupled with increasing cases of genetic disorders, cancers, & infectious diseases.
• The academic & research institutes end-use segment is expected to register the fastest CAGR over the forecast period.
• The growth can be attributed to the greater utility of cell-based assays for the diagnosis of cancers, genetic disorders, and infectious diseases.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Cell-based Assays Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Cell-based Assays Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Cell-based Assays Market: Products & Services Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Cell-based Assays Market: Products & Services Movement Analysis, 2023 & 2030 (USD Million)
• 4.3. Reagents
  • 4.3.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Assay Kits
  • 4.4.1. Assay Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Cell Growth Assays
    • 4.4.2.1. Cell Growth Assays Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Reporter Gene Assays
    • 4.4.3.1. Reporter Gene Assays Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.4. Cell Death Assays
    • 4.4.4.1. Cell Death Assays Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.5. Second Messenger Assays
    • 4.4.5.1. Second Messenger Assays Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Microplates
  • 4.5.1. Microplates Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Probes & Labels
  • 4.6.1. Probes & Labels Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Instruments & Software
  • 4.7.1. Instruments & Software Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Cell Lines
  • 4.8.1. Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8.2. Primary Cell Lines
    • 4.8.2.1. Primary Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8.3. Stem Cell Lines
    • 4.8.3.1. Stem Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8.4. Immortalized Cell Lines
    • 4.8.4.1. Immortalized Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cell-based Assays Market: Application & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Cell-based Assays Market: Application Movement Analysis, 2023 & 2030 (USD Million)
• 5.3. Basic Research
  • 5.3.1. Basic Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Drug Discovery
  • 5.4.1. Drug Discovery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Other Applications
  • 5.5.1. Other Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cell-based Assays Market: End use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Cell-based Assays Market: End-user Movement Analysis, 2023 & 2030 (USD Billion)
• 6.3. Pharmaceutical & Biotechnology Companies
  • 6.3.1. Pharmaceutical & Biotechnology Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.4. Academic & Research Institutes
  • 6.4.1. Academic & Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.5. Contract Research Organizations (CROs)
  • 6.5.1. Contract Research Organizations (CROs)Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Cell-based Assays Market: Regional Estimates & Trend Analysis

• 7.1. Cell-based Assays Market Share, By Region, 2023 & 2030 (USD Billion)
• 7.2. U.S.
  • 7.2.1. U.S. Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.2.3. Canada
    • 7.2.3.1. Canada Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.3. Europe
  • 7.3.1. Europe Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3.2. UK
    • 7.3.2.1. UK Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3.3. Germany
    • 7.3.3.1. Germany Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3.4. France
    • 7.3.4.1. France Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3.5. Italy
    • 7.3.5.1. Italy Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3.6. Spain
    • 7.3.6.1. Spain Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3.9. Norway
    • 7.3.9.1. Norway Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.2. Japan
    • 7.4.2.1. Japan Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.3. China
    • 7.4.3.1. China Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.4. India
    • 7.4.4.1. India Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.5. Australia
    • 7.4.5.1. Australia Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.6. South Korea
    • 7.4.6.1. South Korea Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.7. Thailand
    • 7.4.7.1. Thailand Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.5. Latin America
  • 7.5.1. Latin America Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.6. Middle East and Africa
  • 7.6.1. Middle East and Africa Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.2. South Africa
    • 7.6.2.1. South Africa Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Saudi Arabia Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.4. UAE
    • 7.6.4.1. UAE Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
  • 8.4.1. Bio-Rad Laboratories, Inc.
    • 8.4.1.1. Participant's Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Recent Developments/Strategic Initiatives
  • 8.4.2. Corning Incorporated
    • 8.4.2.1. Participant's Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Recent Developments/Strategic Initiatives
  • 8.4.3. Merck KGaA
    • 8.4.3.1. Participant's Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Recent Developments/Strategic Initiatives
  • 8.4.4. Lonza Group AG
    • 8.4.4.1. Participant's Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Recent Developments/Strategic Initiatives
  • 8.4.5. Charles River Laboratories
    • 8.4.5.1. Participant's Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Recent Developments/Strategic Initiatives
  • 8.4.6. Becton, Dickinson and Company (BD)
    • 8.4.6.1. Participant's Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Recent Developments/Strategic Initiatives
  • 8.4.7. Danaher Corporation
    • 8.4.7.1. Participant's Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Recent Developments/Strategic Initiatives
  • 8.4.8. Promega Corporation
    • 8.4.8.1. Participant's Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Recent Developments/Strategic Initiatives
  • 8.4.9. Thermo Fisher Scientific Inc.
    • 8.4.9.1. Participant's Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Recent Developments/Strategic Initiatives
  • 8.4.10. F. Hoffmann-La Roche Ltd. (Roche Holdings AG)
    • 8.4.10.1. Participant's Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Recent Developments/Strategic Initiatives
  • 8.4.11. Perkin Elmer Inc.
    • 8.4.11.1. Participant's Overview
    • 8.4.11.2. Financial Performance
    • 8.4.11.3. Product Benchmarking
    • 8.4.11.4. Recent Developments/Strategic Initiatives